You have to answer a biomedical question in binary format, i.e. only yes and no are the only acceptable answer formats. A list of paragraphs is provided as context to help you answer the question.

Question: Can Patient-derived organoids (PDOs) recapitulate patient responses in the clinic?

Context: Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from metastatic, heavily pretreated colorectal and gastroesophageal cancer patients recruited in phase 1/2 clinical trials. Phenotypic and genotypic profiling of PDOs showed a high degree of similarity to the original patient tumors. Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses. We compared responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials. Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses.
Phenotypic and genotypic profiling of PDOs showed a high degree of similarity to the original patient tumors.
Patient-derived xenografts (PDX) and patient-derived organoids (PDO) serve as promising tools to identify new drugs with therapeutic potential in PDAC.
Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs
Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs
Molecular profiling of tumor organoids was matched to drug-screening results , suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses
Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
yes